TAR-200 Shows Strong Responses in High-Risk Bladder Cancer
TAR-200, an investigational intravesical drug-releasing system delivering sustained gemcitabine, demonstrated high response rates and durable outcomes in patients with bacillus Calmette-Guérin (BCG)–unresponsive high-risk non–muscle-invasive bladder cancer (NMIBC), according to results from the Phase IIb SunRISe-1 study.